


CLAIMS

~~What is claimed is:~~

1. A compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof,



(I)

wherein,

T is CH, CR₃ or N;

Z₁, Z₂, Z₃, Z₄, and Z₅ are separately independently N or CR₄;

R₁ and R₂ are separately independently H, F, Cl, Br, I, OH or NH₂;

R₃ is F, Cl, Br, I, OH, NH₂, CN, C₁₋₆ alkyl or C₁₋₆ alkoxy, and C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted by 1, 2, or 3 R_a;

R₄ is independently H, F, Cl, Br, I, OH, NH₂, CN, C₁₋₆ alkyl or C₁₋₆ alkoxy, and C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted by 1, 2, or 3 R_b; and

R_a and R_b are separately independently F, Cl, Br, I, OH or NH₂,

wherein when T is CH and R₂ is F, then R₁ is F, Cl, Br, I, OH or NH₂.

2. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R₁ and R₂ are separately independently H, Cl, or F.

3. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R₃ is F, Cl, Br, I, OH, NH₂, CN, C₁₋₃ alkyl or C₁₋₃ alkoxy, and the C₁₋₃ alkyl and C₁₋₃ alkoxy are optionally substituted by 1, 2, or 3 R_a.

4. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 3, wherein R₃ is F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₂CH₃ or OCH₃, and the CH₃, CH₂CH₃ and OCH₃ are optionally substituted by 1, 2, or 3 R_a.

5. The compound, the isomer thereof or pharmaceutically acceptable salt thereof according to claim 4, wherein R₃ is F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₂F, CHF₂, CF₃, CH₂CH₃ or OCH₃.




6. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R₄ is independently H, F, Cl, Br, I, OH, NH₂, CN, C₁₋₃ alkyl or C₁₋₃ alkoxy, and the C₁₋₃ alkyl and C₁₋₃ alkoxy are optionally substituted by 1, 2, or 3 R_b.

7. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 6, wherein R₄ is H, F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₂CH₃, or OCH₃.




8. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 or 5, wherein T is CH, N, C(NH₂), C(OCH₃) or C(CHF₂).

9. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 or 7, wherein Z₁, Z₂, Z₃, Z₄, and Z₅ are separately independently N, CH, C(OCH₃) or C(CH₃).

10. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof

according to claim 9, wherein the moiety  is  or .


11. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof

according to claim 10, wherein the moiety  is  or .


12. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof

according to claim 1, wherein the moiety  is  or .


13. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-7, which is selected from:




(I-1)




(I-2)




(I-3)



(I-4)



(I-5)





(I-6)

wherein,


R₁, R₂, R₃, and R₄ are defined in any one of claims 1-7.


14. A compound of the following formula, an isomer thereof or a pharmaceutically acceptable salt thereof:





15. The compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to claim 14, which is selected from:





16. A pharmaceutical composition, comprising a therapeutically effective amount of the compound, the pharmaceutically acceptable salt thereof or the isomer thereof according to any one of claims 1-15 as active ingredients, and a pharmaceutically acceptable carrier.

17. Use of the compound, the isomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-15 or the pharmaceutical composition according to claim 16 in the manufacture of a drug for treating DNA-PK related diseases.

18. The use according to claim 17, wherein the DNA-PK related ~~drug is a drug for~~ disease comprises treating tumors.